117 related articles for article (PubMed ID: 23177726)
21. In vivo imaging of folate receptor positive tumor xenografts using novel 68Ga-NODAGA-folate conjugates.
Fani M; Tamma ML; Nicolas GP; Lasri E; Medina C; Raynal I; Port M; Weber WA; Maecke HR
Mol Pharm; 2012 May; 9(5):1136-45. PubMed ID: 22497506
[TBL] [Abstract][Full Text] [Related]
22. Relevance of folic acid/polymer ratio in targeted PEG-epirubicin conjugates.
Canal F; Vicent MJ; Pasut G; Schiavon O
J Control Release; 2010 Sep; 146(3):388-99. PubMed ID: 20621587
[TBL] [Abstract][Full Text] [Related]
23. The therapeutic efficiency of FP-PEA/TAM67 gene complexes via folate receptor-mediated endocytosis in a xenograft mice model.
Arote RB; Hwang SK; Lim HT; Kim TH; Jere D; Jiang HL; Kim YK; Cho MH; Cho CS
Biomaterials; 2010 Mar; 31(8):2435-45. PubMed ID: 20022105
[TBL] [Abstract][Full Text] [Related]
24. Synthesis and in vitro/in vivo evaluation of 99mTc-labeled folate conjugates for folate receptor imaging.
Lu J; Pang Y; Xie F; Guo H; Li Y; Yang Z; Wang X
Nucl Med Biol; 2011 May; 38(4):557-65. PubMed ID: 21531293
[TBL] [Abstract][Full Text] [Related]
25. Delivery of zoledronic acid encapsulated in folate-targeted liposome results in potent in vitro cytotoxic activity on tumor cells.
Shmeeda H; Amitay Y; Gorin J; Tzemach D; Mak L; Ogorka J; Kumar S; Zhang JA; Gabizon A
J Control Release; 2010 Aug; 146(1):76-83. PubMed ID: 20462513
[TBL] [Abstract][Full Text] [Related]
26. Folate targeting enables durable and specific antitumor responses from a therapeutically null tubulysin B analogue.
Leamon CP; Reddy JA; Vetzel M; Dorton R; Westrick E; Parker N; Wang Y; Vlahov I
Cancer Res; 2008 Dec; 68(23):9839-44. PubMed ID: 19047164
[TBL] [Abstract][Full Text] [Related]
27. Folate-targeted dinitrophenyl hapten immunotherapy: effect of linker chemistry on antitumor activity and allergic potential.
Lu Y; You F; Vlahov I; Westrick E; Fan M; Low PS; Leamon CP
Mol Pharm; 2007; 4(5):695-706. PubMed ID: 17784727
[TBL] [Abstract][Full Text] [Related]
28. In vivo structural activity and optimization studies of folate-tubulysin conjugates.
Reddy JA; Dorton R; Dawson A; Vetzel M; Parker N; Nicoson JS; Westrick E; Klein PJ; Wang Y; Vlahov IR; Leamon CP
Mol Pharm; 2009; 6(5):1518-25. PubMed ID: 19630399
[TBL] [Abstract][Full Text] [Related]
29. Synthesis and preclinical evaluation of a folic acid derivative labeled with 18F for PET imaging of folate receptor-positive tumors.
Bettio A; Honer M; Müller C; Brühlmeier M; Müller U; Schibli R; Groehn V; Schubiger AP; Ametamey SM
J Nucl Med; 2006 Jul; 47(7):1153-60. PubMed ID: 16818950
[TBL] [Abstract][Full Text] [Related]
30. Engineering folate-drug conjugates to target cancer: from chemistry to clinic.
Vlahov IR; Leamon CP
Bioconjug Chem; 2012 Jul; 23(7):1357-69. PubMed ID: 22667324
[TBL] [Abstract][Full Text] [Related]
31. Synthesis of novel folate conjugated fluorescent nanoparticles for tumor imaging.
Hou J; Zhang Q; Li X; Tang Y; Cao MR; Bai F; Shi Q; Yang CH; Kong DL; Bai G
J Biomed Mater Res A; 2011 Dec; 99(4):684-9. PubMed ID: 21913319
[TBL] [Abstract][Full Text] [Related]
32. Folate receptor-mediated enhanced and specific delivery of far-red light-activatable prodrugs of combretastatin A-4 to FR-positive tumor.
Nkepang G; Bio M; Rajaputra P; Awuah SG; You Y
Bioconjug Chem; 2014 Dec; 25(12):2175-88. PubMed ID: 25351441
[TBL] [Abstract][Full Text] [Related]
33. Synthesis and evaluation of a novel lipophilic folate receptor targeting ligand.
Liu Y; Xu S; Teng L; Yung B; Zhu J; Ding H; Lee RJ
Anticancer Res; 2011 May; 31(5):1521-5. PubMed ID: 21617205
[TBL] [Abstract][Full Text] [Related]
34. Design and regioselective synthesis of a new generation of targeted chemotherapeutics. Part 1: EC145, a folic acid conjugate of desacetylvinblastine monohydrazide.
Vlahov IR; Santhapuram HK; Kleindl PJ; Howard SJ; Stanford KM; Leamon CP
Bioorg Med Chem Lett; 2006 Oct; 16(19):5093-6. PubMed ID: 16870437
[TBL] [Abstract][Full Text] [Related]
35. Intracellular delivery of redox cycler-doxorubicin to the mitochondria of cancer cell by folate receptor targeted mitocancerotropic liposomes.
Malhi SS; Budhiraja A; Arora S; Chaudhari KR; Nepali K; Kumar R; Sohi H; Murthy RS
Int J Pharm; 2012 Aug; 432(1-2):63-74. PubMed ID: 22531856
[TBL] [Abstract][Full Text] [Related]
36. Imaging sites of infection using a 99mTc-labeled folate conjugate targeted to folate receptor positive macrophages.
Henne WA; Rothenbuhler R; Ayala-Lopez W; Xia W; Varghese B; Low PS
Mol Pharm; 2012 May; 9(5):1435-40. PubMed ID: 22468849
[TBL] [Abstract][Full Text] [Related]
37. Combined muta- and semisynthesis: a powerful synthetic hybrid approach to access target specific antitumor agents based on ansamitocin P3.
Taft F; Harmrolfs K; Nickeleit I; Heutling A; Kiene M; Malek N; Sasse F; Kirschning A
Chemistry; 2012 Jan; 18(3):880-6. PubMed ID: 22170289
[TBL] [Abstract][Full Text] [Related]
38. Folate-targeted enzyme prodrug cancer therapy utilizing penicillin-V amidase and a doxorubicin prodrug.
Lu JY; Lowe DA; Kennedy MD; Low PS
J Drug Target; 1999; 7(1):43-53. PubMed ID: 10614814
[TBL] [Abstract][Full Text] [Related]
39. Ligand binding and kinetics of folate receptor recycling in vivo: impact on receptor-mediated drug delivery.
Paulos CM; Reddy JA; Leamon CP; Turk MJ; Low PS
Mol Pharmacol; 2004 Dec; 66(6):1406-14. PubMed ID: 15371560
[TBL] [Abstract][Full Text] [Related]
40. Development of a fluorescence polarization binding assay for folate receptor.
Kornilova AY; Algayer B; Breslin M; Addona GH; Uebele V
Anal Biochem; 2013 Jan; 432(2):59-62. PubMed ID: 23022041
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
